FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242079040> ?p ?o ?g. }

• W4242079040 abstract "Chronic inflammatory demyelinating polyradiculoneuropathy is an immune mediated disorder characterised by progressive or relapsing symmetrical motor or sensory symptoms and signs in more than one limb, developing over at least two months. It may cause prolonged periods of disability and even death. Several uncontrolled studies have suggested a beneficial effect of intravenous immunoglobulin.To review systematically the evidence from randomised controlled trials concerning the efficacy and safety of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.We used the Search Strategy of the Cochrane Neuromuscular Disease Review Group to search the Disease Group register and other databases for randomised controlled trials from 1985 onwards.Randomised controlled studies examining the effects of any dose of intravenous immunoglobulin versus placebo, plasma exchange or corticosteroids in patients with definite or probable chronic inflammatory demyelinating polyradiculoneuropathy. Outcome measures had to include one of the following: a disability score, the Medical Research Council sum score, electrophysiological data or walking distance. Studies which reported the frequency of adverse effects were used to assess the safety of treatment.Two reviewers independently reviewed literature searches to identify potentially relevant trials, scored their quality and extracted data independently. For dichotomous data, we calculated relative risks, and for continuous data, effect sizes (for definition see statistical analysis section) and weighted pooled effect sizes. Statistical uncertainty was expressed in 95% confidence intervals. Sensitivity analysis excluding studies with quality scores below A 0.50 and below B 0.75 was planned but not performed as all studies had quality scores above 0.75.Six randomised controlled trials were considered eligible including 170 patients. Four studies on 113 patients compared intravenous immunoglobulin against placebo. One trial with 17 patients compared intravenous immunoglobulin with plasma exchange in a cross-over design and one trial compared intravenous immunoglobulin with prednisolone in 32 patients. A significantly higher proportion of patients improved in disability within one month after the onset of intravenous immunoglobulin treatment as compared with placebo (relative risk 3.17, 95% confidence interval 1.74 to 5.75). Whether all these improvements are equally clinically relevant cannot be deduced from this analysis because each trial used a different disability scale with a unique definition of a significant improvement. To overcome this problem an attempt was made to transform the various disability scales to the modified Rankin score. In three trials including 87 patients this transformation could be carried out. A significantly higher proportion of patients improved one point after intravenous immunoglobulin treatment compared to placebo (relative risk 2.47, 95% confidence interval 1.02 to 6.01). The effect size for change of mean disability score at six weeks comparing intravenous immunoglobulin with plasma exchange revealed no difference between the two therapies (effect size -0.07, 95% confidence interval -0.76 to 0.63.) The proportion of patients with a significant improvement did not differ significantly between prednisolone and intravenous immunoglobulin (relative risk of 0.91 (95% CI 0.50 to 1.68). Also, no difference in mean improvement on the disability scale was found at two weeks (effect size -0.12, 95% confidence interval -0.68 to 0.45) or six weeks (effect size -0.07, 95% confidence interval -0.63 to 0.50) between prednisolone and intravenous immunoglobulin. There were no statistically significant differences in frequencies of side effects between the three types of treatment.The evidence from randomised controlled trials shows that intravenous immunoglobulin improves disability for at least two to six weeks compared with placebo, with a number needed to treat of three. During this period it has similar efficacy to plasma exchange and oral prednisolone. Since intravenous immunoglobulin, plasma exchange and prednisolone seem to be equally effective, it is currently uncertain which of these treatments should be the first choice. Cost, side effects, duration of treatment, dependency on regular hospital visits and ease of administration all have to be considered before such a decision can be made." @default.
• W4242079040 created "2022-05-12" @default.
• W4242079040 creator A5021652823 @default.
• W4242079040 creator A5042215764 @default.
• W4242079040 creator A5077611966 @default.
• W4242079040 creator A5081891032 @default.
• W4242079040 date "2002-04-22" @default.
• W4242079040 modified "2023-10-13" @default.
• W4242079040 title "Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy" @default.
• W4242079040 cites W1965138496 @default.
• W4242079040 cites W1967160380 @default.
• W4242079040 cites W1967264035 @default.
• W4242079040 cites W1981564440 @default.
• W4242079040 cites W1983883058 @default.
• W4242079040 cites W1991027093 @default.
• W4242079040 cites W1997980896 @default.
• W4242079040 cites W2014771575 @default.
• W4242079040 cites W2016490271 @default.
• W4242079040 cites W2038987655 @default.
• W4242079040 cites W2040050809 @default.
• W4242079040 cites W2040160619 @default.
• W4242079040 cites W2041172301 @default.
• W4242079040 cites W2044828334 @default.
• W4242079040 cites W2051306572 @default.
• W4242079040 cites W2056063821 @default.
• W4242079040 cites W2056518988 @default.
• W4242079040 cites W2058501416 @default.
• W4242079040 cites W2062055705 @default.
• W4242079040 cites W2063169348 @default.
• W4242079040 cites W2080861718 @default.
• W4242079040 cites W2091703526 @default.
• W4242079040 cites W2093602775 @default.
• W4242079040 cites W2093997579 @default.
• W4242079040 cites W2094965101 @default.
• W4242079040 cites W2118159460 @default.
• W4242079040 cites W2119762128 @default.
• W4242079040 cites W2127180052 @default.
• W4242079040 cites W2129138169 @default.
• W4242079040 cites W2154028856 @default.
• W4242079040 cites W2160683521 @default.
• W4242079040 cites W2166114233 @default.
• W4242079040 cites W2166118538 @default.
• W4242079040 cites W2169077473 @default.
• W4242079040 cites W2314097961 @default.
• W4242079040 cites W2414786344 @default.
• W4242079040 cites W2616639792 @default.
• W4242079040 cites W2965965202 @default.
• W4242079040 cites W3021516239 @default.
• W4242079040 cites W4210885122 @default.
• W4242079040 cites W4247546324 @default.
• W4242079040 doi "https://doi.org/10.1002/14651858.cd001797" @default.
• W4242079040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12076423" @default.
• W4242079040 hasPublicationYear "2002" @default.
• W4242079040 type Work @default.
• W4242079040 citedByCount "34" @default.
• W4242079040 countsByYear W42420790402013 @default.
• W4242079040 countsByYear W42420790402016 @default.
• W4242079040 countsByYear W42420790402017 @default.
• W4242079040 countsByYear W42420790402022 @default.
• W4242079040 countsByYear W42420790402023 @default.
• W4242079040 crossrefType "reference-entry" @default.
• W4242079040 hasAuthorship W4242079040A5021652823 @default.
• W4242079040 hasAuthorship W4242079040A5042215764 @default.
• W4242079040 hasAuthorship W4242079040A5077611966 @default.
• W4242079040 hasAuthorship W4242079040A5081891032 @default.
• W4242079040 hasConcept C118552586 @default.
• W4242079040 hasConcept C126322002 @default.
• W4242079040 hasConcept C142724271 @default.
• W4242079040 hasConcept C168563851 @default.
• W4242079040 hasConcept C1862650 @default.
• W4242079040 hasConcept C187212893 @default.
• W4242079040 hasConcept C197934379 @default.
• W4242079040 hasConcept C204787440 @default.
• W4242079040 hasConcept C21715850 @default.
• W4242079040 hasConcept C27081682 @default.
• W4242079040 hasConcept C2777052087 @default.
• W4242079040 hasConcept C2778691916 @default.
• W4242079040 hasConcept C2780052305 @default.
• W4242079040 hasConcept C44249647 @default.
• W4242079040 hasConcept C522805319 @default.
• W4242079040 hasConcept C71924100 @default.
• W4242079040 hasConcept C95190672 @default.
• W4242079040 hasConceptScore W4242079040C118552586 @default.
• W4242079040 hasConceptScore W4242079040C126322002 @default.
• W4242079040 hasConceptScore W4242079040C142724271 @default.
• W4242079040 hasConceptScore W4242079040C168563851 @default.
• W4242079040 hasConceptScore W4242079040C1862650 @default.
• W4242079040 hasConceptScore W4242079040C187212893 @default.
• W4242079040 hasConceptScore W4242079040C197934379 @default.
• W4242079040 hasConceptScore W4242079040C204787440 @default.
• W4242079040 hasConceptScore W4242079040C21715850 @default.
• W4242079040 hasConceptScore W4242079040C27081682 @default.
• W4242079040 hasConceptScore W4242079040C2777052087 @default.
• W4242079040 hasConceptScore W4242079040C2778691916 @default.
• W4242079040 hasConceptScore W4242079040C2780052305 @default.
• W4242079040 hasConceptScore W4242079040C44249647 @default.
• W4242079040 hasConceptScore W4242079040C522805319 @default.
• W4242079040 hasConceptScore W4242079040C71924100 @default.
• W4242079040 hasConceptScore W4242079040C95190672 @default.
• W4242079040 hasLocation W42420790401 @default.

• next